Result of General Meeting

CRISM Therapeutics Corporation

15 June 2026

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

15 June 2026

CRISM Therapeutics Corporation

('CRISM', 'CRISM Therapeutics' or the 'Company')

Result of General Meeting

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that all Resolutions were duly passed unanimously on a show of hands at the Company's General Meeting, which was held today at 10:00 a.m.

The votes cast were as follows:

Resolution	Votes for	% for	Votes against	% against	Abstentions
1	7,895,490	99.97	2,182	0.03	996
2	7,895,440	99.97	2,232	0.03	996

Andrew Webb, Executive Chairman of CRISM Therapeutics, said: "We would like to thank our existing shareholders as well as welcome new investors who have supported and participated in this funding round, which has now successfully completed.  When combined with the grant finance that we recently announced, the Company is now in a strong financial position to execute on our stated strategy and we look forward to reporting on further milestones in the weeks ahead."

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the 22,500,000 Conditional Placing Shares and 2,450,000 Retail Offer Shares ('Admission'). It is expected that Admission will become effective and that trading will commence in the Conditional Placing Shares and Retail Offer Shares at 8.00 a.m. on 16 June 2026. The Conditional Placing Shares and the Retail Offer Shares will rank pari passu with the Company's existing Ordinary Shares.

In addition, 25,000,000 Warrants, exercisable at a price of 15 pence per ordinary share and expiring on 16 December 2027, have been granted to subscribers for the Placing Shares.

Following Admission, the total issued share capital of the Company will consist of 79,185,266 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 79,185,266 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Capitalised terms not defined have the same meaning as given to them in the Company's Circular dated 27 May 2026.

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, Executive Chairman Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

 

END